My notes from the Confrenece Call:
- SI to discuss if the trial can be funded by academic institutions. Invetory for the trial is ready with the company, no more expense required.
- If this trial is successful, approval to come for both Padeatric as well as Adults.
- It's going to be an easier and shorter trial as patients are easy to enrol due to no other therapy available.
- Duration of Trial, Number of Patients required for trial and if the Trial will be RCT (with or without control arm) will be decided after FDA meeting.
- EAP continuation to be discussed and confirmed in meeting with FDA
SI dodged one critical question by John Hester: He just didn't answer that and asked for disconnection of lines and wrap-up of conference.
- Company's financial situation and plans to manage funds with short runway left with existing funds.
Overall, IMO, it's a thunderstorm in near term, more dilution, but not all over yet, it's not a step forward, not well timed though.
There is still hope and better hope than what it was 6 months ago.
- Forums
- ASX - By Stock
- MSB
- Ann: Update on BLA for Graft Versus Host Disease
Ann: Update on BLA for Graft Versus Host Disease, page-201
-
- There are more pages in this discussion • 817 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.06 |
Change
0.030(2.91%) |
Mkt cap ! $1.210B |
Open | High | Low | Value | Volume |
$1.05 | $1.09 | $1.03 | $5.796M | 5.430M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 15990 | $1.06 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.08 | 48632 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 15990 | 1.060 |
3 | 33766 | 1.055 |
2 | 38526 | 1.050 |
4 | 79050 | 1.045 |
3 | 54455 | 1.040 |
Price($) | Vol. | No. |
---|---|---|
1.075 | 48632 | 3 |
1.080 | 108135 | 6 |
1.085 | 103276 | 9 |
1.090 | 239204 | 9 |
1.095 | 74283 | 8 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |